drugset / Trial / NCT03605680

A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

NCT03605680

RandomizedParallel-groupDouble-blindTreatment

Summary

This study evaluates the efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit/hyperactivity disorder (ADHD). Participants will either receive a twice-daily dose of centanafadine sustained-release tablets, or twice-daily placebo.

Timeline

Start
2019-01-16
Primary completion
2020-04-11
Completion
2020-04-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Centanafadine Small molecule 100 mg Oral
Subject Centanafadine Small molecule 200 mg Oral